Latest News and Press Releases

Aðalfundur Alvotech S.A. verður haldinn föstudaginn 7. júní 2024, kl. 09.00 CEST á skrifstofu Arendt & Medernach S.A að 41A Avenue John F. Kennedy, L-1855 Lúxemborg. Drög af dagskrá fundarins er...

The Annual General Meeting of Alvotech S.A. will be held on Friday June 7, 2024, at 09.00 a.m. CEST at the premises of Arendt & Medernach S.A. at 41A, Avenue John F. Kennedy L-1855 Luxembourg,...

REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...

Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrsta ársfjórðungs 2024 eftir lokun markaða í Bandaríkjunum, þriðjudaginn 21. maí nk.  Þá mun Alvotech halda kynningarfund fyrir...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...

Alvotech (NASDAQ: ALVO) tilkynnti í dag að félagið taki þátt í árlegri heilbrigðisráðstefnu BofA Securities, sem haldin verður dagana 14. – 15. maí í Las Vegas, Nevadafylki Bandaríkjanna. Fulltrúar úr...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be...

REYKJAVIK, Iceland, May 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

Alvotech mun framleiða líftæknilyfjahliðstæðu sína í háum styrk með útskiptileika við Humira (adalimumab) fyrir Quallent Pharmaceuticals, dótturfélag Cigna Alvotech (NASDAQ: ALVO) tilkynnti í dag...

Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S....